Study and treatment of post Lyme disease (STOP-LD): A randomized double masked clinical trial

Neurology

Volumn 60, Issue 12, 2003, Pages 1923-1930

  Krupp, L B ^a   Hyman, L G ^a   Grimson, R ^a   Coyle, P K ^a   Melville, P ^a   Ahnn, S ^a   Dattwyler, R ^a   Chandler, B ^a  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE; MEMBRANE PROTEIN;

ADULT; ANAPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; FATIGUE; FEMALE; HOSPITALIZATION; HUMAN; LYME DISEASE; MALE; MENTAL FUNCTION; PERSISTENT INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0038714584     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000071227.23769.9E     Document Type: Article

References (38)

1. Burgdorferi W, Barbour AG, Hayes SF, Grunwaldt E, Davis JP. Lyme disease - a tick borne spirochetosis? Science 1982;216:1317-1319.
2. Steere AC. Lyme disease. N Engl J Med 2001;345:115-125.
3. Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis - randomized comparison of ceftriaxone vs. penicillin. Lancet 1988;2:1191-1194.
4. Rahn DW, Malawista SE. Lyme disease: recommendations for diagnosis and treatment. Ann Intern Med 1991;114:472-481.
5. Sigal LH. Summary of the first 100 patients seen at a Lyme disease referral center. Am J Med 1990;88:577-581.
6. Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. JAMA 1993;2:1812-1816.
7. Reid CM, Schoen RT, Evans J, Rosenberg JC, Horwitz RI. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann Intern Med 1998;128:354-362.
8. Fallon BA, Tager F, Fein L, et al. Repeated antibiotic treatment in chronic Lyme disease. J Lyme Dis Found 1999;6:94-101.
9. Liegner KB, Duray P, Agricola M, et al. Lyme disease and the clinical spectrum of antibiotic responsive chronic meningoencephalomyelitides. J Spirochetal Tick-borne Dis 1997;4:61-73.
10. Ettlestad PJ, Campbell GL, Welbel SF, et al. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis 1995;171: 356-361.
11. Patel R, Grogg KL, Edwards WD, Wright AJ, Schwenk NM. Death from inappropriate therapy for lyme disease. Clin Infect Dis 2000;31:1107-1109.
12. Trieb J, Fernandez A, Haass A, Grauer, Halzer G, Woessner R. Clinical and serologic follow-up in patients with neuroborreliosis. Neurology 1998;51:1489-1491.
13. Bujak DI, Weinstein A, Dornbush RL. Clinical and neurocognitive features of the post Lyme syndrome. J Rheumatol 1996;23:1392-1397.
14. Gaudino EA, Coyle PK, Krupp LB. Post-Lyme syndrome and chronic fatigue syndrome: neuropsychiatric similarities and differences. Arch Neural 1997;54:1372-1376.
15. Asch ES, Bujak DI, Weiss M, Peterson MGE, Weinstein A. Lyme disease: an infectious and postinfectious syndrome. J Rheumatol 1994;21: 454-461.
16. Shadick NA, Phillips CB, Sangha O. Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. Ann Intern Med 1999;131:919-926.
17. Centers for Disease Control. Case definitions for public health surveillance. MMWR 1990;39:19-21.
18. Krupp LB, LaRocca NC, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-1123.
19. Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. J Psychosom Res 1993;37:753-762.
20. Melzack R. The short form McGill pain questionnaire. Pain 1987;30:1991.
21. Ware J, Sherbourne C. The MOS 36-item short-form health survey (SF-36) I. Conceptual framework and item selection. Med Care 1992;30:473-483.
22. Radloff L. The CES-D Scale. A self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
23. First MB, Spitzer RL, Gibbon M, Williams JBW. Instruction manual for the Structured Clinical Interview for DSM-IV-R. New York: New York State Psychiatric Institute, 1996.
24. Coyle PK, Deng Z, Schutzer SE, Belman AL, Krupp LB, Luft B. Detection of Borrelia burgdorferi antigens in cerebrospinal fluid. Neurology 1993;43:1093-1097.
25. Krupp LB, Coyle P, Doscher C, et al. Fatigue therapy in multiple sclerosis: results of a double blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995;45:1956-1961.
26. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002;72:179-183.
27. Kleinman L, Zodet MW, Hakim Z, et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C. Qual Life Res 2000;9:499-508.
28. Sheean G, Murray N, Rothwell J, Miller D, Thompson A. An open labeled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain 1998;121:967-975.
29. Pollina DA, Sliwinski M, Squires NK, Krupp LB. Cognitive processing speed in Lyme disease. Neuropsychiatry Neuropsychol Behav Neurol 1999;12:1-12.
30. Pollina DA, Scheffer S, Krupp LB. Psychological states and neuropsychological performances in chronic Lyme disease. Appl Neuropsychol 1999;6:19-26.
31. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556.
32. Simes RJ. An improved Bonferroni procedure for multiple procedure for multiple tests of significance. Biometrika 1986;73:751-754.
33. Krupp LB, Masur D, Schwartz D, Fernquist S, Lagenbach L, Halperin J. Cognitive functioning in Lyme borreliosis. Arch Neurol 1991;52:403-410.
34. Taylor RR, Jason LA, Torres A. Fatigue rating scales: an empirical comparison. Psychol Med 2000;30:849-856.
35. Tilley BC, Alarcon GS, Heyse SP, et al. Minocycline in rheumatoid arthritis: a 48-week, double blind, placebo-controlled trial. Ann Intern Med 1995;122:81-89.
36. Caperton EM, Heim-Duthoy KL, Matzke GR, Peterson PK, Johnson RC. Ceftriaxone therapy of chronic inflammatory arthritis: a doubleblind placebo controlled trial. Arch Intern Med 1990;150:1677-1682.
37. Geisler MW, Sliwinski M, Masur D, Krupp LB. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 1996;53:185-188.
38. Klempner M, Hu L, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001;345:85-92.